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Compliance with National Cholesterol Education Program Adult Treatment Panel III (NCEP) guidelines has been 
shown to significantly reduce incident cardiovascular events. We investigated physicians’ compliance with NCEP 
guidelines to reduce cardiovascular disease (CVD) risk in a population infected with HIV.
Methods 
We analyzed HIV Outpatient Study (HOPS) data, following eligible patients from January 1, 2002, or first HOPS visit 
thereafter to calculate 10-year cardiovascular risk (10yCVR), until September 30, 2009, death, or last office visit. We 
categorized participants into four 10yCVR strata, according to guidelines determined by NCEP, the Infectious Disease 
Society of America, and the Adult AIDS Clinical Trials Group. We calculated percentages of patients treated for 
dyslipidemia and hypertension, calculated percentages of patients who achieved recommended goals, and categorized 
them by 10yCVR stratum.
Results 
Of 2,005 patients analyzed, 33.7% had fewer than 2 CVD risk factors. For patients who had 2 or more risk factors, 
10yCVR was less than 10% for 28.2%, 10% to 20% for 18.2%, and higher than 20% for 20.0% of patients. Of patients 
eligible for treatment, 81% to 87% were treated for elevated low-density lipoprotein cholesterol/non–high-density 
lipoprotein cholesterol (LDL-C/non–HDL-C), 2% to 11% were treated for low HDL-C, 56% to 91% were treated for high 
triglycerides, and 46% to 69% were treated for hypertension. Patients in higher 10yCVR categories were less likely to 
meet treatment goals than patients in lower 10yCVR categories.
Conclusion 
At least one-fifth of contemporary HOPS patients have a 10yCVR higher than 20%, yet a large percentage of at-risk 
patients who were eligible for pharmacologic treatment did not receive recommended interventions and did not reach 
recommended treatment goals. Opportunities exist for CVD prevention in the HIV-infected population.
Introduction
Compliance with guidelines established in 2001 by the National Cholesterol Education Program Adult Treatment Panel 
III (NCEP) for primary and secondary prevention of myocardial infarction significantly reduces incident cardiovascular 
events (1–5). In 2003, the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group published a 
modification of the 2001 NCEP guidelines to address management of cardiovascular risk (CVR) in HIV-1 infected 
people (6). In addition to describing management of traditional CVR factors, the modification included 
recommendations for altering antiretroviral therapy (ART). We analyzed the degree to which the modified NCEP 
guidelines have been followed by physicians in the HIV Outpatient Study (HOPS) cohort and the effectiveness of these 
interventions in reaching NCEP treatment goals designed to reduce incident cardiovascular events.
Methods
HIV Outpatient Study cohort
The HOPS is an ongoing, prospective, observational cohort study of HIV-infected patients receiving care in 10 
participating HIV clinics (4 universities, 2 public clinics, 4 private clinics) in 8 US cities (Chicago, Illinois; Denver, 
Colorado; Stony Brook, New York; Oakland/San Leandro, California; Philadelphia, Pennsylvania; Tampa, Florida; and 
Washington, DC) since March 1993. The cohort represents a convenience sample of patients receiving HIV care at the 
sites; enrollment varies by clinic size. Patient data, including sociodemographic characteristics, symptoms, signs, 
diagnoses, treatments, and laboratory values, are abstracted from medical charts and entered into an electronic 
database by trained staff. Data are reviewed for quality and analyzed centrally. The HOPS protocol is reviewed and 
approved annually by the Centers for Disease Control and Prevention and each local site’s institutional review board. 
This analysis used HOPS data from January 1, 2002, through September 30, 2009.
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Study population
Entry criteria for participation in HOPS are documented HIV infection and informed consent to participate in the study. 
To assess achievement of treatment goals based on the 2001 NCEP guidelines, we included HOPS patients active on or 
after January 1, 2002, to allow clinicians the opportunity to respond to the 2001 guidelines. We defined “active” patients 
as those who had attended 2 or more office visits since January 1, 2002. The categorization of patients by their baseline 
10-year CVR (10yCVR) required that eligible patients have had 2 or more blood pressure readings recorded and at least 
1 fasting lipid panel obtained as baseline measurements any time between 12 months before and up to 9 months after 
the baseline date, and at least 1 year after baseline. Patients were followed until September 30, 2009, death, or last 
office visit.
We assessed whether the percentages of patients treated per modified NCEP guidelines and achieving recommended 
goals at any time during the follow-up period differed across progressively higher categories of baseline 10yCVR and 
according to key baseline demographic characteristics. We also calculated rates of incident cardiovascular events per 
100 person-years of observation by 10yCVR group for descriptive purposes because of the small number of 
cardiovascular events.
Classification of patients into 10yCVR categories
We categorized HOPS patients by baseline 10yCVR into 4 categories per NCEP guidelines (2). These guidelines 
categorize risk using a combination of the Framingham 10-year absolute risk for developing coronary heart disease 
(CHD) and conditions defined as CHD equivalents (eg, diabetes mellitus [diabetes], prior cardiovascular event). A 
Framingham risk calculation was not performed in patients who had low risk (ie, ≤1 major risk factor) and for whom 
10yCVR was less than 10%. A Framingham risk calculation was performed among patients with 2 or more major risk 
factors, and they were categorized as follows: those with a 10yCVR of less than 10% were at moderate risk, those with a 
10yCVR of 10% to 20% were at moderately high risk, and those with either CHD, a CHD equivalent, or a 10yCVR higher 
than 20% were at high risk.
Major risk factors for CHD included cigarette smoking (past or current), hypertension (systolic/diastolic blood pressure 
≥140/90 mm Hg; or for patients diagnosed with diabetes or chronic renal insufficiency, ≥130/80 mm Hg; or 
prescription of antihypertensive therapy with a diagnosis of hypertension, regardless of blood pressure), elevated serum 
low-density lipoprotein cholesterol (LDL-C), serum high-density lipoprotein cholesterol (HDL-C) less than 40 mg/dL 
for men and less than 50 mg/dL for women, a family history of premature CHD (first-degree male relative aged <55 y, 
first-degree female relative aged <65 y), and older age (men, ≥45 y; women, ≥55 y). CHD equivalents are conditions that 
pose a CHD event risk equal to the risk for having a new CHD event in people with established CHD; these include 
known noncardiac vascular disease (peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid 
artery disease) and diabetes. We compared the 2,005 patients with those who were excluded because of missing 1 or 
more required lipid or blood pressure readings.
Clinical interventions for lipid and blood pressure management are made according to 10yCVR risk category. A switch 
in ART at any time during the study period from a regimen associated with lipid abnormalities or insulin resistance to a 
regimen less likely to have these associations was considered an appropriate intervention (7–14).
NCEP treatment goals and thresholds for medical intervention
Conditions for modification are 1) LDL-C in people with triglyceride levels ≤200 mg/dL and 2) non–HDL-C (total 
cholesterol minus HDL-C) when triglycerides exceed 200 mg/dL. Recommended values of LDL-C and non–HDL-C at 
which to initiate therapeutic lifestyle changes and/or drug therapy, as well as target values (goal), differ by each of the 4 
NCEP-defined 10yCVR categories (Table 1). We included 3 additional conditions for modification to reduce CVR: low 
HDL-C, hypertriglyceridemia, and hypertension. We defined the HDL-C value below which to initiate lipid-modifying 
therapy and at or above which we considered goal to have been achieved as 40 mg/dL in men and 50 mg/dL in women. 
We also defined a triglyceride level of ≥500 mg/dL (the level at which triglycerides adversely affect LDL-C metabolism) 
as the level at which medical intervention should be initiated, with a triglyceride level of less than 500 mg/dL as goal. 
We considered treatment of triglycerides between 200 mg/dL and 499 mg/dL as optional. Treated hypertensive 
patients achieved goal if blood pressure was less than 140/90 mm Hg (or <130/80 mm Hg with concurrent diabetes or 
chronic renal insufficiency).
We defined the presence of metabolic syndrome as having at least 3 of the following: fasting triglycerides of at least 150 
mg/dL, low HDL-C, fasting blood glucose of at least 110 mg/dL, systolic blood pressure of at least 130 mm Hg or 
diastolic blood pressure of at least 85 mm Hg, and a body mass index (BMI) of at least 28.9 kg/m  for men or 24.9 
kg/m  for women. 
We defined appropriate treatment as prescription of a 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase inhibitor 
(statin), with or without ezetimibe, or bile acid sequestrants for elevated LDL-C/non-HDL-C (Table 1); of nicotinic acid, 
documentation of exercise, or both for low HDL-C; of fibrates or omega-3 fatty acids for hypertriglyceridemia, and of 
antihypertensives for hypertension. However, data on initiation of therapeutic lifestyle changes such as increased 
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exercise were not systematically collected in this cohort. We also considered changes in ART regimens as appropriate 
treatment.
Statistical analyses
Summaries of descriptive data, univariate analyses, and Cochrane–Armitage tests for trend were conducted with SAS 
version 9.2 (SAS Institute, Inc, Cary, North Carolina). We compared the distributions of categorical variables using a 
likelihood ratio, continuity-adjusted χ  test, or Fisher exact test, and we compared the distributions of continuous 
variables with a Wilcoxon rank-sum test for 2-group comparisons. We used a χ  test and Kruskal–Wallis test for 
comparisons of more than 2 groups. We computed incidence rates of cardiovascular events per 100 person-years of 
observation for each 10yCVR category and compared them across 10yCVR categories using StatCalc (EpiInfo 2000, 
Centers for Disease Control and Prevention, Atlanta, Georgia). Proportion confidence intervals were calculated using 
mid-P exact confidence limits (15). Statistical associations with 2-sided P values less than .05 were considered 
significant.
Results
Our study population of 2,005 HOPS patients (baseline median age, 42 y; median CD4+ T cell count, 395 cells/mm ) 
was predominantly male (76%) and racially/ethnically diverse (52% non-Hispanic white, 33% non-Hispanic black, and 
12% Hispanic); 55% of patients were current or former tobacco users at baseline. Seventeen percent of patients had no 
ART exposure, 77.7% had exposure to highly active ART (HAART) (45.3% had prior mono- or dual-antiretroviral [ARV] 
exposures; 32.4% had HAART only), and 5.1% were classified as having unknown or missing data on ARV exposure. Of 
the 2,005 HOPS patients analyzed, 675 were categorized at baseline as low risk, 565 as moderate risk, 365 as moderately
high risk, and 400 as high risk. Median follow-up after baseline was approximately 5.5 years and did not differ 
significantly across 10yCVR categories (Table 2).
At baseline, as 10yCVR increased, the percentage of people with the following characteristics increased significantly: 
those with a diagnosis of either hypertension or metabolic syndrome; median serum total cholesterol and triglycerides; 
and those prescribed lipid-lowering agents. Median serum HDL-C decreased significantly with increasing 10yCVR 
categories, whereas LDL-C, the distribution by race/ethnicity, and baseline use of ART did not vary consistently (Table 
2).
Excluded patients were significantly younger (median age, 40 vs 42 y); more likely to be male (82.0% vs 76.4%); more 
likely to be white (56.2% vs 52.3%); more likely to be privately insured (65.5% vs 57.2%); and less likely to have had an 
AIDS-defining illness (22.0% vs 36.3%), diabetes (4.3% vs 9.5%), hypertension (27.5% vs 51.7%), or BMI higher than 30 
kg/m  (12.7% vs 19.4%); and more likely to have unknown or missing ARV history (17.0% vs 5.1%) at baseline.
As 10yCVR increased, the percentage of people with each cardiovascular condition of interest increased (Table 3). The 
percentage of patients treated among those patients with each condition of interest also increased; the highest 
percentage was treated for high LDL-C and hypertriglyceridemia. However, the percentage of patients treated according 
to modified NCEP guidelines and who met guideline-defined goals at any time during the follow-up period for each 
condition decreased across each of the 4 CVR categories, particularly in the high-risk group.
Women, nonwhites, and patients with public insurance or no insurance were treated for hypertension per guidelines 
more often than men, whites, or patients with private insurance, despite a lower representation of the former patients in 
the higher CVR categories. Pharmacologic treatment of low HDL-C was more frequent in whites and men but overall 
treatment rates were low. Management of LDL-C/non-HDL-C, HDL-C, and triglycerides was similar when these groups 
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Figure 1. Percentage of patients with condition treated per National Cholesterol Education Program Adult Treatment 
Panel III (NCEP) guidelines, by sex, the HIV Outpatient Study, January 2002–September 2009. Error bars indicate 95% 
confidence intervals. Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol. [A tabular version of this figure is also available.]
Figure 2. Percentage of patients with condition treated per National Cholesterol Education Program Adult Treatment 
Panel III (NCEP) Guidelines, by race/ethnicity, the HIV Outpatient Study, January 2002–September 2009. Error bars 
represent 95% confidence intervals. Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol. [A tabular version of this figure is also available.]
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Figure 3. Percentage of patients with condition treated per National Cholesterol Education Program Adult Treatment 
Panel III (NCEP) Guidelines, by payer, the HIV Outpatient Study, January 2002–September 2009. Error bars represent 
95% confidence intervals. Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol. [A tabular version of this figure is also available.]
Incidence of cardiovascular events (per 100 person-years) increased with increasing 10yCVR category: 0.38 (14 events) 
in the low-risk group compared with 0.89 (27 events) in the moderate-risk group, 2.24 (45 events) in the moderately 
high-risk group, and 2.98 (62 events) in the high-risk group (all P < .01 compared with the low-risk group).
Discussion
HIV-infected patients are at higher risk and have a higher incidence of cardiovascular events than the general public (16
–22). In our cohort, 38.2% of patients were in either the moderately high-risk or high-risk categories, of whom 77.9% 
were current or former smokers, 74.2% had hypertension, 71.5% had baseline elevated LDL-C levels, 70.5% had low 
HDL-C levels, and 35.8% had metabolic syndrome. The percentage of patients with high LDL-C/non-HDL-C and 
triglyceride levels, low HDL-C levels, and hypertension generally increased with increasing 10yCVR category. Although 
most affected patients were prescribed recommended therapy for high LDL-C/non-HDL-C and hypertriglyceridemia, 
only half were treated for hypertension and very few were treated pharmacologically for low HDL-C. We also observed 
lower frequency of hypertension treatment among men, people who were white, and people who were privately insured; 
these lower frequencies were not explained by colinearity or differences in 10yCVR distribution.
Several studies have demonstrated increases in total cholesterol, LDL-C, HDL-C and triglycerides after initiating ART in 
antiretroviral-naïve patients (23–32). In untreated advanced HIV infection, levels of total cholesterol, LDL-C, and HDL-
C are typically low. It is unclear to what extent the lipid elevations observed after initiating treatment of HIV infection 
were an adverse effect of ART versus a return to health (33). In light of the increased CVR faced by HIV-infected 
patients, focusing efforts on improving lipid profiles and controlling hypertension as recommended in the modified 
NCEP recommendations seems prudent.
HDL-C deserves additional attention. Normalizing HDL-C levels is a tertiary goal of the NCEP guidelines (34). HIV-
infected patients characteristically have low HDL-C levels, and although levels rise with ART, they rarely normalize (33). 
We also found a high percentage of people (62% men, 65% women) in our cohort with low HDL-C measurements 
compared with the 1999–2002 National Health and Nutrition Examination Survey (NHANES III) population (33% 
men, 20% women) (35). Only 5.4% of patients in our study received pharmacologic treatment of HDL-C, of whom only 
26.5% achieved target levels. Possible explanations for low compliance may include concern about side effects, pill 
burden, designation of HDL-C as a tertiary target, and pharmaceutical marketing emphasis on triglyceride elevations.
Although much attention has focused on the effect of ART on elevating triglyceride levels, only 8.3% of patients in our 
cohort had levels exceeding 500 mg/dL at baseline. Of those patients, 83.8% received triglyceride-lowering therapy and 
78.6% of those patients had reductions of triglycerides to less than 500 mg/dL. Elevated triglycerides directly contribute 
little to increased CVR. Triglycerides exceeding 500 mg/dL interfere with the release of LDL-C from small dense 
atherogenic particles, resulting in deposition of these particles into atheromatous plaques (36). Statins contribute to 
expression of LDL-C receptors with consequent reduction of the circulating LDL-C substrate. Reducing triglycerides to 
less than 500 mg/dL enhances the effectiveness of statin therapy via this mechanism.
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Although other cohort studies of HIV-infected patients have evaluated CVD risk factors, including 10yCVR, few to our 
knowledge have assessed physician adherence to guidelines for management of these conditions (18,37–39). We found 
that 38.2% of our study population had a 10yCVR at or higher than 10% (moderately high risk and high risk) compared 
with 22% to 26% in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study (40). In an analysis of the 
Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS), Kaplan et al defined 
moderate CVD risk as a 10yCVR of 15% to 25% and high CVD risk as a 10yrCVR of 25% or higher or having a diagnosis 
of diabetes. They found that 2% of men and 1% of women had a moderate predicted CVD risk and 17% of men and 12% 
of women had a high predicted CVD risk (18).
Comparing NHANES III data with those from the HOPS cohort, 30.0% versus 41.5% of people had elevated baseline 
LDL-C. When considering only moderately high-risk and high-risk groups, 68.0% versus 71.5% of patients had high 
LDL-C, of whom 25.0% versus 83.7% received treatment. Of those patients treated, 39.1% versus 59.3% in the 
moderately high-risk group and 22.3% versus 33.5% in the high-risk group met NCEP goals. Although comparisons of 
NHANES III and HOPS data are complicated by differences in study design, population sociodemographic 
characteristics, laboratory measurements of lipids, and ascertainment of treatment interventions, findings suggest that 
there is still a significant opportunity for improvement in CVD risk management in HOPS patients.
This study, which used routinely collected medical abstraction data from HIV outpatients, had several limitations. Our 
inclusion criteria, which required certain baseline examinations, may have enriched our analysis cohort in people whom 
clinicians considered to be at higher risk of CVD and who had warranted those examinations. Whether the excluded 
patients were considered lower risk by their physicians or had unrecognized risk factors necessarily limits the overall 
findings in our study. We also cannot infer reasons for lack of intervention when apparently indicated. Failure to initiate 
recommended interventions may have resulted from patients deferring or declining therapy, contraindications to these 
therapies not recorded in HOPS chart abstractions, or clinician oversight. CVD risk factor data were not systematically 
charted, precluding our ability to assess whether interventions resulted in sustained responses over time. We did not 
have adequate information on family history of cardiovascular events in first-degree relatives, a major CHD risk factor. 
The absence of these data would likely lead us to underestimate the true prevalence of CVR in our population. 
Furthermore, we did not have information on waist size for most patients. We substituted BMI at or above 28.9 kg/m  
for men and at or above 24.9 kg/m  for women for waist size greater than 40 inches in men and greater than 35 inches 
in women, when measured, for our estimation of metabolic syndrome, guided by findings from prior studies in HIV 
cohorts (33,41). The data on pharmacotherapeutic treatments may have been recorded incompletely, and patients may 
have received treatments outside of the HOPS clinics (eg, cardiology specialist consultations) that were also not 
captured by chart abstraction. Finally, we could not account for therapeutic lifestyle change interventions such as 
intentional smoking cessation or weight loss, improved diet, or increased exercise; these data are not collected 
systematically in the HOPS.
Our findings suggest that HOPS participants who comprise a heterogeneous convenience sample of HIV-infected 
patients seen at 10 HIV specialty clinics in the United States have significantly greater CVD risk than both the general 
US population and participants in other HIV cohorts. A large percentage of at-risk patients who were eligible for 
pharmacologic treatment did not receive recommended interventions and did not reach recommended treatment goals. 
As HIV-infected patients live longer, it is imperative that clinicians minimize CVD risk by optimizing patients’ lipid 
profiles and blood pressure and helping patients who use tobacco products to quit. Intensified educational efforts are 
needed and further research is warranted to understand the barriers to initiating recommended interventions and to 
achieving recommended treatment goals that are unique to HIV-infected patients.
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Table 1. Low-Density Lipoprotein Cholesterol (LDL-C) Goals, by 
Cardiovascular Risk (CVR) Category, According to the 2001 National 
Cholesterol Education Program Adult Treatment Panel III (NCEP) Guidelines When 
Serum Triglycerides Values Are <200 mg/dL
CVR Category
LDL-C Level at Which to Initiate 
Therapeutic Lifestyle Changes, 
mg/dL






Low risk, ≤1 major risk factor
(10yCVR <10%)
≥160 ≥190 <160
Moderate risk, ≥2 major risk 
factors (10yCVR <10%)
≥130 ≥160 <130
Moderately high risk, ≥2 major 
risk factors (10yCVR 10%–20%)
≥130 ≥130 <130
High risk, ≥2 major risk factors 
or CHD equivalent or (10yCVR 
>20%)
≥100 ≥130 <100
Abbreviations: CHD, coronary heart disease (coronary heart disease or coronary heart disease equivalent per NCEP 
guidelines); HDL-C, high-density lipoprotein cholesterol. 
 When serum triglycerides are ≥ 200 mg/dL, non-HDL-C goals are used instead of LDL-C goals. Non-HDL-C goals are 30 
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Table 2. Characteristics of Patients (N = 2,005), by 10-Year Cardiovascular 





















Risk), ≥2 Risk 







Age, y, median 42 38 41 47 48 <.001
Male sex 1,532 
(76)
451 (67) 405 (72) 350 (96) 326 (82) <.001
Race/ethnicity
White, non-Hispanic 1,048 
(52)
304 (45) 276 (49) 252 (69) 216 (54)
<.001Black, non-Hispanic 657 (33) 251 (37) 199 (35) 73 (20) 134 (34)
Hispanic 239 (12) 93 (14) 71 (13) 31 (8) 44 (11)
Other 61 (3) 27 (4) 19 (3) 9 (2) 6 (2)
Year of HOPS entry
1998 or earlier 856 (43) 247 (37) 210 (37) 176 (48) 223 (56)
<.0011999–2005 1,149 
(57)
428 (63) 355 (63) 189 (52) 177 (44)
Private insurance 1,147 
(57)
420 (62) 293 (52) 233 (64) 201 (50) <.001
History of IDU 227 (11) 37 (5) 90 (16) 38 (10) 62 (16) <.001
Prior AIDS-defining 
illness
728 (36) 209 (31) 204 (36) 139 (38) 176 (44) <.001
Cell count/viral load




314 (47) 296 (52) 191 (52) 215 (54) .06
Nadir CD4+ T cell 
count, cells/mm , 
median
197 218 187 190 180 .27
CD4+ T cell count, 
cells/mm , median
395 396 358 401 415 .002
Peak viral load, 
copies/mL, median
5,985 7,790 19,712 1,911 2,384 <.001
Viral load, copies/mL, 
median
419 745 908 200 200 <.001
Viral load <400 
copies/mL
988 (49) 305 (45) 244 (43) 211 (58) 228 (57) <.001
Alcohol use, drinks/week
Missing information 127 (6) 49 (7) 32 (6) 18 (5) 28 (7)
<.001
0 977 (49) 322 (48) 284 (50) 146 (40) 225 (56)
<7 689 (34) 242 (36) 192 (34) 144 (39) 111 (28)

























Risk), ≥2 Risk 







>14 88 (4) 22 (3) 27 (5) 26 (7) 13 (3)
BMI, kg/m
Missing information 120 (6) 47 (7) 36 (6) 21 (6) 16 (4)
.005≤25 909 (45) 331 (49) 261 (46) 160 (44) 157 (39)
>25 976 (49) 297 (44) 268 (47) 184 (50) 227 (57)
Hypertension 1,036 
(52)
112 (17) 356 (63) 230 (63) 338 (85) <.001
Diabetes mellitus 190 (9) 0 0 0 190 (48) <.001




164 (24) 348 (62) 296 (81) 300 (75) <.001
Blood lipid panel measurement
Total cholesterol, 
mg/dL, median
204 197 181 226 238 <.001
LDL cholesterol, 
mg/dL, median
105 108 94 114 107 <.001
HDL cholesterol, 
mg/dL, median
37 44 35 35 35 <.001
Non-HDL cholesterol, 
mg/dL, median
164 151 142 186 199 <.001
Triglycerides, mg/dL, 
median
163 126 162 200 225 <.001
Metabolic syndrome 516 (26) 85 (13) 157 (28) 103 (28) 171 (43) <.001
Antiretroviral therapy
Efavirenz 452 (23) 157 (23) 136 (24) 66 (18) 93 (23) .14
Nevirapine 213 (11) 65 (10) 63 (11) 38 (10) 47 (12) .70
Protease inhibitor, 
unboosted
222 (11) 62 (9) 72 (13) 41 (11) 47 (12) .23
Protease inhibitor, 
boosted
626 (31) 205 (30) 171 (30) 126 (35) 124 (31) .51
Zidovudine or 
Stavudine
775 (39) 233 (35) 230 (41) 143 (39) 169 (42) .043
Didanosine 273 (14) 78 (12) 72 (13) 62 (17) 61 (15) .07
Abacavir 443 (22) 139 (21) 132 (23) 81 (22) 91 (23) .68
Tenofovir 561 (28) 174 (26) 181 (32) 92 (25) 114 (29) .055
Lipid-lowering agents
Statin drug/ezitimibe 245 (12) 42 (6) 31 (5) 49 (13) 123 (31) <.001
Fibrate 116 (6) 13 (2) 16 (3) 26 (7) 61 (15) <.001


























Risk), ≥2 Risk 









5.5 5.5 5.5 5.8 5.1 .32
Lipid-lowering agents
Statin drug/ezitimibe 562 (28) 119 (18) 109 (19) 125 (34) 209 (52) <.001
Fibrate 235 (12) 39 (6) 53 (9) 54 (15) 89 (22) <.001





442 (65) 380 (67) 260 (71) 271 (68) .30
Antihypertensives 633 (32) 52 (8) 212 (38) 136 (37) 233 (58) <.001
Incident CVD 148 (7) 14 (2) 27 (5) 45 (12) 62 (16) <.001
Abbreviations: IDU, intravenous drug use; AIDS, acquired immunodeficiency syndrome; BMI, body mass index; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; ARV, antiretroviral. 
 Values presented as n (%) unless otherwise indicated. 
 χ  test for binary variables or Kruskal–Wallis test for continuous variables. 
 Non-HDL cholesterol equals total cholesterol minus HDL cholesterol. 
 Defined as the presence of any 3 of the following 5 risk factors: hypertension (≥130 mm Hg over ≥85 mm Hg), elevated 
triglycerides (≥150 mg/dL), low HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women), fasting glucose ≥110 mg/dL, 
abdominal obesity (BMI ≥28.9 kg/m  for men and ≥24.9 kg/m  for women).  
 Treatment of either high LDL-cholesterol/non-HDL-cholesterol or hypertriglyceridemia can include the following ARV 
changes: Zidovudine/Stavudine to Abacavir or Tenofovir; Abacavir to Tenofovir; boosted protease inhibitor to unboosted 
protease inhibitor; any protease inhibitor to Efavirenz or Nevirapine; Efavirenz to Nevirapine; boosted Indinavir or Lopinavir 
to boosted Darunavir, Atazanavir, fos-Amprenavir, or Saquinavir/Fortovase.
 
Table 3. Treatment of Patients (N = 2,005) for High LDL-C/Non-HDL-C, 
Low HDL-C, Hypertriglyceridemia, and Hypertension, by 10-Year 




% (n/N) With 
Condition
% (n/N) Treated Per 
Guidelines
% (n/N) Treated Who Met 
NCEP Goals
High LDL-C/non-HDL-C P < .001 P = .68 P < .001
Low risk 15.9 (107/675) 81.3 (87/107) 81.6 (71/87)
Moderate risk 31.5 (178/565) 86.5 (154/178) 62.3 (96/154)
Moderately high risk 62.2 (227/365) 83.3 (189/227) 59.3 (112/189)
High risk 80.0 (320/400) 84.1 (269/320) 33.5 (90/269)
Low HDL-C P < .001 P < .001 P = .42
Low risk 41.6 (281/675) 2.9 (8/281) 50.0 (4/8)
Moderate risk 78.4 (443/565) 1.6 (7/443) 14.3 (1/7)
Moderately high risk 67.7 (247/365) 8.1 (20/247) 20.0 (4/20)
High risk 73.0 (292/400) 11.3 (33/292) 27.3 (9/33)
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Condition/CVR 
Category
% (n/N) With 
Condition
% (n/N) Treated Per 
Guidelines
% (n/N) Treated Who Met 
NCEP Goals
Low risk 2.4 (16/675) 56.3 (9/16) 88.9 (8/9)
Moderate risk 5.8 (33/565) 90.9 (30/33) 80.0 (24/30)
Moderately high risk 12.3 (45/365) 82.2 (37/45) 78.4 (29/37)
High risk 18.3 (73/400) 87.7 (64/73) 76.6 (49/64)
Hypertension P < .001 P < .001 P < .001
Low risk 16.6 (112/675) 46.4 (52/112) 67.3 (35/52)
Moderate risk 63.0 (356/565) 59.6 (212/356) 66.0 (140/212)
Moderately high risk 63.0 (230/365) 59.1 (136/230) 64.0 (87/136)
High risk 84.5 (338/400) 68.9 (233/338) 46.4 (108/233)
Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; NCEP, National 
Cholesterol Education Program Adult Treatment Panel III. 
 See text for definitions of 10-year cardiovascular disease risk categories and definitions of high LDL-C/non-HDL-C, low HDL-
C, hypertriglyceridemia, and hypertension. 
 Eligible patients treated per modified NCEP guidelines within 2 years of baseline date. Treatment of either high LDL-C/non-
HDL-C or hypertriglyceridemia can include the following ARV changes: Zidovudine/Stavudine to Abacavir or Tenofovir; 
Abacavir to Tenofovir; boosted protease inhibitor to unboosted protease inhibitor; any protease inhibitor to Efavirenz or 
Nevirapine; Efavirenz to Nevirapine; boosted Indinavir or Lopinavir to boosted Darunavir, Atazanavir, fos-Amprenavir, or 
Saquinavir/Fortovase. 
 Treated patients who met modified NCEP goals after starting treatment and before the end of observation in the study. 
 Likelihood ratio χ  test.
Post-Test Information
To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the 
following, related, multiple-choice questions. To complete the questions (with a minimum 70% passing score) and earn 
continuing medical education (CME) credit, please go to http://www.medscape.org/journal/pcd . Credit cannot be 
obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You 
must be a registered user on Medscape.org. If you are not registered on Medscape.org, please click on the “Register” link 
on the right hand side of the website to register. Only one answer is correct for each question. Once you successfully 
answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content 
of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact 
CME@webmd.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in 
the US as evidence of participation in CME activities. For further information on this award, please refer to 
http://www.ama-assn.org/ama/pub/category/2922.html . The AMA has determined that physicians not licensed in 
the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements 
that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of 
participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA 
PRA CME credit certificate and present it to your national medical association for review. 
Post-Test Questions
Article Title: Provider Compliance with Guidelines for Management of 
Cardiovascular Risk in Patients Infected With the Human Immunodeficiency 
Virus
CME Questions
You are seeing a 50-year-old man with a 10-year history of HIV infection. His body mass index is 29 kg/m , and 
you are concerned with his cardiovascular risk. Which of the following statements regarding cardiovascular risk 
factors among patients with HIV is most accurate? 
1.
Persons with HIV infection are generally at the same risk of cardiovascular disease as persons without HIVA.
LDL-C is typically high among patients with HIV who have not received antiretroviral therapy (ART)B.
ART increases levels of multiple classes of serum lipidsC.
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What should you consider regarding the distribution of cardiovascular risk among patients in the current study? 2.
More than 90% of participants had 2 or more cardiovascular risk factorsA.
One fifth of participants had a 10-year cardiovascular risk (10yCVR) of over 20%B.
Hypertriglyceridemia was the most common cardiovascular risk factorC.
High LDL-C was the most common cardiovascular risk factorD.
Upon chart review, the patient you are seeing has multiple cardiovascular risk factors. Which of the following risk 






The patient has hypertension. Which of the following variables was a risk factor for not receiving appropriate 




Borderline blood pressure valueC.
Private health insuranceD.
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1. The activity supported the learning objectives.
Strongly Disagree    Strongly Agree 
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2. The material was organized clearly for learning to occur. 
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3. The content learned from this activity will impact my practice. 
Strongly Disagree    Strongly Agree 
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4. The activity was presented objectively and free of commercial bias. 
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